VAXCYTE, INC. Total Shareholder Rtn Amt
VAXCYTE, INC. (PCVX) reported Total Shareholder Rtn Amt of $176 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-23.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-23
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $176.00 DEF 14A · filed 2026-04-23 |
| 2024-12-31 | $313.00 DEF 14A · filed 2026-04-23 |
| 2023-12-31 | $240.00 DEF 14A · filed 2026-04-23 |
| 2022-12-31 | $183.00 DEF 14A · filed 2026-04-23 |
| 2021-12-31 | $91.00 DEF 14A · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |